Determination of Body Awareness and the Functional Movement in Patients With COPD

Kronik Obstrüktif Akciğer Hastalığında Vücut Farkındalığı, Fonksiyonel Hareket Analizi ve İlişkili Parametrelerin Belirlenmesi

The aim of this study is to investigate body awareness and functional movement in patients with Chronic Obstructive Pulmonary Disease (COPD) compared to healthy controls.

Study Overview

• Status: Not yet recruiting
• Conditions: Pain; Pulmonary Disease, Chronic Obstructive; Postural; Defect; Movement, Abnormal

Detailed Description

It is aimed at investigating body awareness, and functional movement, and related factors in patients with COPD. The secondary purpose is to determine correlations between body awareness and functional movement, respiratory muscle strength and endurance, daily living activities, posture, and pain threshold in this study. The determination of correlations between functional movement, respiratory pattern, and functional exercise capacity is also purposed. In accordance with these purposes, at least 30 patients with COPD will be included and at least 30 healthy controls will be included. Tests and questionnaires will be used in order to determine the severity of disease. Lung function test and respiratory muscle strength and endurance test will be performed. Six Minute Walk Test will be performed for functional exercise capacity. To evaluate posture, the Corbin Postural Assessment Scale will be used. Pain and pain threshold will be assessed via Visual Analog Scale and an algometer, respectively. Body Awareness Rating Questionnaire will be used for evaluating body awareness. To evaluate daily living activities, Glittre Activities of Daily Living Test will be used. The Functional Movement Screen Test will be used for functional movement analysis. According to the results to be obtained, body awareness and functional movement will be determined in patients with COPD. It will guide professional working in this field.

• Study Type: Observational
• Enrollment (Estimated): 60

Contacts and Locations

• Study Contact: Name: Aynur Demirel, PhD; Phone Number: +905545295057; Email: aynur.demirel@hacettepe.edu.tr
• Study Contact Backup: Name: Hidaye Yamikan, PT,MSc; Phone Number: +905349898724; Email: hidaye.yamikan@hacettepe.edu.tr

Study Locations

• Turkey
  • Ankara, Turkey, 06100
    • Hacettepe University
    • Contact: Aynur Demirel; Phone Number: 178 +905545295057; Email: aynur.demirel@hacettepe.edu.tr
    • Contact: hidaye yamikan; Phone Number: +905349898724; Email: hidaye.yamikan@hacettepe.edu.tr
    • Sub-Investigator: hidaye yamikan
    • Sub-Investigator: cansu akkus
  • Ankara, Turkey, 06100
    • Aynur Demirel

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Patients with COPD and aged matched healthy controls will be included in this study.

Description

Inclusion Criteria for Chronic Obstructive Pulmonary Disease Group

• Being under 55 years old
• To be literate,
• Having volunteered to participate in the research,
• Stage 1-2-3-4 according to the Classification of Airflow Limitation in COPD (GOLD) system,
• Being clinically stable for the last 2 weeks.

Exclusion Criteria for Chronic Obstructive Pulmonary Disease Group

• Having history of lung cancer, sarcoidosis, tuberculosis and/or lung surgery,
• Communication problems,
• Having a severe psychiatric disorder.

Inclusion Criteria for Healthy Control Group

• Not having any cardiopulmonary system disease or chronic systemic disease,
• To be literate,
• Being under 55 years old
• Be willing to participate in the study.
• Not having balance problems, musculoskeletal, neurological and psychiatric disorders that could prevent performing the test procedures.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
study group; Patients with Chronic Obstructive Pulmonary Disease
control group; Aged-matched healthy controls

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of functional movement	Functional movement analysis will be performed via The Functional Movement Screen.	1 day
Evaluation of Body Awareness	Body awareness will be assessed via Body Awareness Rating Questionnaire. It consists of 24 questions and each item is scored on a 7-point Likert-type scale. The total score ranges from 24 to168. A Higher scores indicate higher body awareness.	1 day

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Functional exercise capacity	Functional exercise capacity will be assessed via Six minute walk test.	1 day
Respiratory muscle strength	Respiratory muscle strength will be assessed via a using a mouth pressure device according to American Thoracic Society/ European Respiratory Society guidelines.	1
Respiratory muscle endurance	Respiratory muscle endurance will be assessed using the maximal incremental loading technique and constant loading technique using a device according to the European Respiratory Society guidelines.	1 day
Pain Severity	Severity of pain will be assessed via Visual Analog Scale. Zero point is defined as no pain and ten point as unbearable pain. Total point ranges from 0 to 10.	1 day
Pain threshold	Pain threshold will be assessed via an algometer.	1 day
Posture	Posture will be examined via the Corbin Postural Assessment Scale. The total points of the Corbin Postural Assessment Scale range from 0 to 28 points. A higher point represents worse posture.	1 day
Daily living activities	Daily living activities will be evaluated via Glittre Activities of Daily Living Test.	1 day
Severity of disease	Global Initiative for Chronic Obstructive Pulmonary Disease and Global Initiative for Chronic Obstructive Pulmonary ABE assessment Tool will be used for severity of disease. According to the Global Initiative for Chronic Obstructive Pulmonary Disease, the severity of airflow limitation (Forced Expiratory Volume in 1 s) was determined as mild (≥ 80%), moderate (50-80%), severe (30-50%), and very severe (<30%). According to Global Initiative for Chronic Obstructive Pulmonary A,B,E assessment Tool, patients classified group A, B, and E using symptom status and airflow limitation.	1 day
Dyspnea	The Modified Medical Research Council will be used for patients with COPD. The Modified Medical Research Council consist of five grades. A higher grades represents severe dyspnea level.	1 day
Symptoms	Chronic Obstructive Pulmonary Disease Assessment Test will be used to determine symptoms. The total score of Chronic Obstructive Pulmonary Disease Assessment Test changes from 0 to 40 points, and 10 points is the accepted cut-off point for COPD.	1 day

Collaborators and Investigators

• Sponsor: Hacettepe University

Study record dates

Study Major Dates

• Study Start (Estimated): March 8, 2024
• Primary Completion (Estimated): March 8, 2025
• Study Completion (Estimated): March 8, 2026

Study Registration Dates

• First Submitted: February 27, 2024
• First Submitted That Met QC Criteria: March 5, 2024
• First Posted (Actual): March 7, 2024

Study Record Updates

• Last Update Posted (Actual): March 7, 2024
• Last Update Submitted That Met QC Criteria: March 5, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Central Nervous System Diseases; Nervous System Diseases; Respiratory Tract Diseases; Lung Diseases; Neurologic Manifestations; Disease Attributes; Movement Disorders; Lung Diseases, Obstructive; Chronic Disease; Pulmonary Disease, Chronic Obstructive; Dyskinesias
• Other Study ID Numbers: SBA 23/391

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No